Story perspectives

BrainsWay's Fast-Track TMS Treatment Gains FDA Approval

9/18/2025

35 4

Summary

Story summary

BrainsWay Ltd. received FDA clearance for an accelerated Deep TMS treatment for major depressive disorder (MDD) and anxiety.
The new protocol shortens treatment from four weeks to six days, with five sessions daily.
Clinical trials showed similar outcomes to standard treatment, with comparable depression score reductions and remission rates.
No severe adverse events were reported, confirming safety.
Following the announcement, BrainsWay's stock rose 11.9%, indicating positive market response.

1 of 1

Story summary

BrainsWay Ltd. received FDA clearance for an accelerated Deep TMS treatment for major depressive disorder (MDD) and anxiety.
The new protocol shortens treatment from four weeks to six days, with five sessions daily.
Clinical trials showed similar outcomes to standard treatment, with comparable depression score reductions and remission rates.
No severe adverse events were reported, confirming safety.
Following the announcement, BrainsWay's stock rose 11.9%, indicating positive market response.